ALLO - Allogene Therapeutics Inc Company Cash Volume

Corporate emblem and logo of allogene.com (ALLO)

The cash position on the GURU.Markets chart demonstrates Allogene Therapeutics (ALLO) diversified approach to developing CAR-T therapies against various tumors, while the 0.30 metric reflects current dynamics. Strong clinical interest in off-the-shelf blood cancer treatments is driving demand. Meanwhile, the business's financial stability relies on research results, remaining independent of market cycles.

Allogene Corp - ALLO Company Cash Balance (period 07/04/2022 - 11/21/2026)

Financial and market metric breakdowns for Allogene (ALLO)

- stock value and consensus price forecast:
Analysis of all company metrics:ALLO Allogene Therapeutics
Brand item of allogene.com

This indicator measures the volume of highly liquid assets, determining the business's ability to cover operating expenses and invest in growth without incurring external debt. For Allogene Therapeutics (ALLO), this reserve is critical when scaling the production of finished CAR-T therapies. By analyzing the company's cash history, an investor assesses the burn rate during the technology patenting period. A stable liquidity balance confirms the resilience of the business model and enhances its investment potential.